Table 2 ESRP1 and ESRP2 and prostate cancer phenotype. Contingency tables and the chi2-test were performed on 12,140 (ESRP1) and 12,962 (ESRP2) analyzable cancers
ESRP1 immunostaining | ESRP2 immunostaining | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Parameter | n evaluable | negative (%) | low (%) | high (%) | p value | n evaluable | negative (%) | low (%) | high (%) | p value |
All cancers | 12,140 | 61.4 | 36 | 2.6 | 12,962 | 58.4 | 36.4 | 5.2 | ||
Tumor stage | ||||||||||
pT2 | 7634 | 64.32 | 33.84 | 1.85 | < 0.0001 | 8163 | 61.67 | 34.61 | 3.72 | < 0.0001 |
pT3a | 2759 | 58.54 | 38.02 | 3.44 | 2950 | 54.44 | 38.68 | 6.88 | ||
pT3b-pT4 | 1698 | 52.47 | 43.05 | 4.48 | 1798 | 50.28 | 40.49 | 9.23 | ||
Gleason grade | ||||||||||
≤ 3 + 3 | 2097 | 70.48 | 28.47 | 1.05 | < 0.0001 | 2299 | 67.33 | 30.23 | 2.44 | < 0.0001 |
3 + 4 | 6529 | 63.06 | 35.2 | 1.75 | 6906 | 59.98 | 36.1 | 3.92 | ||
3 + 4 Tert.5 | 592 | 63.01 | 33.95 | 3.04 | 618 | 54.85 | 39.97 | 5.18 | ||
4 + 3 | 1214 | 51.65 | 42.92 | 5.44 | 1291 | 51.98 | 39.74 | 8.29 | ||
4 + 3 Tert.5 | 895 | 52.29 | 43.69 | 4.02 | 948 | 49.05 | 41.56 | 9.39 | ||
≥ 4 + 4 | 725 | 45.38 | 46.9 | 7.72 | 793 | 43.51 | 42.24 | 14.25 | ||
Lymph node metastasis | ||||||||||
N0 | 7343 | 59.14 | 37.98 | 2.87 | < 0.0001 | 7767 | 56.43 | 37.96 | 5.61 | < 0.0001 |
N+ | 931 | 51.34 | 43.93 | 4.73 | 1004 | 47.91 | 41.43 | 10.66 | ||